To further evaluate the clinical relevance of MAOA and HIF1A, we assessed whether elevated MAOA levels in prostate cancers treated with neoadjuvant chemotherapy associated with increased HIF1A in vivo. This evidence concerns the gene HIF1A and prostate cancer.